tetano
Editor, Senior Moderator
Eur J Med Res
. 2021 Sep 26;26(1):115.
doi: 10.1186/s40001-021-00590-y.
Role of fatty liver in coronavirus disease 2019 patients' disease severity and hospitalization length: a case-control study
Arash Ziaee[SUP] 1 [/SUP], Ghodsiyeh Azarkar[SUP] 2 3 [/SUP], Masood Ziaee[SUP] 4 [/SUP]
Affiliations
Abstract
Background and purpose: Fatty liver is one of the most common pre-existing illnesses; it can cause liver injury, leading to further complications in coronavirus disease 2019 patients. Our goal is to determine if pre-existing fatty liver is more prevalent in hospitalized COVID-19 patients compared to patients admitted before the SARS-CoV-2 pandemic and determine the disease severity among fatty liver patients.
Experimental approach: This retrospective study involves a case and a control group consisting of 1162 patients; the case group contains hospitalized COVID-19 patients with positive PCR tests and available chest CT-scan; the control group contains patients with available chest CT-scan previous to the COVID-19 pandemic. Patients' data such as liver Hounsfield unit, hospitalization length, number of affected lobes, and total lungs involvement score were extracted and compared between the patients.
Results: The findings indicate that 37.9% of hospitalized COVID-19 patients have a pre-existing fatty liver, which is significantly higher (P < 0.001) than the prevalence of pre-existing fatty liver in control group patients (9.02%). In comparison to hospitalized non-fatty liver COVID-19 patients, data from hospitalized COVID-19 patients with fatty liver indicate a longer hospitalization length (6.81 ± 4.76 P = 0.02), a higher total lungs involvement score (8.73 ± 5.28 P < 0.001), and an increased number of affected lobes (4.42 ± 1.2 P < 0.001).
Conclusion: The statistical analysis shows fatty liver is significantly more prevalent among COVID-19 against non-COVID-19 patients, and they develop more severe disease and tend to be hospitalized for more extended periods.
Keywords: Coronavirus disease 2019 (COVID-19); Fatty liver; Illness severity; Stay length.
. 2021 Sep 26;26(1):115.
doi: 10.1186/s40001-021-00590-y.
Role of fatty liver in coronavirus disease 2019 patients' disease severity and hospitalization length: a case-control study
Arash Ziaee[SUP] 1 [/SUP], Ghodsiyeh Azarkar[SUP] 2 3 [/SUP], Masood Ziaee[SUP] 4 [/SUP]
Affiliations
- PMID: 34565475
- DOI: 10.1186/s40001-021-00590-y
Abstract
Background and purpose: Fatty liver is one of the most common pre-existing illnesses; it can cause liver injury, leading to further complications in coronavirus disease 2019 patients. Our goal is to determine if pre-existing fatty liver is more prevalent in hospitalized COVID-19 patients compared to patients admitted before the SARS-CoV-2 pandemic and determine the disease severity among fatty liver patients.
Experimental approach: This retrospective study involves a case and a control group consisting of 1162 patients; the case group contains hospitalized COVID-19 patients with positive PCR tests and available chest CT-scan; the control group contains patients with available chest CT-scan previous to the COVID-19 pandemic. Patients' data such as liver Hounsfield unit, hospitalization length, number of affected lobes, and total lungs involvement score were extracted and compared between the patients.
Results: The findings indicate that 37.9% of hospitalized COVID-19 patients have a pre-existing fatty liver, which is significantly higher (P < 0.001) than the prevalence of pre-existing fatty liver in control group patients (9.02%). In comparison to hospitalized non-fatty liver COVID-19 patients, data from hospitalized COVID-19 patients with fatty liver indicate a longer hospitalization length (6.81 ± 4.76 P = 0.02), a higher total lungs involvement score (8.73 ± 5.28 P < 0.001), and an increased number of affected lobes (4.42 ± 1.2 P < 0.001).
Conclusion: The statistical analysis shows fatty liver is significantly more prevalent among COVID-19 against non-COVID-19 patients, and they develop more severe disease and tend to be hospitalized for more extended periods.
Keywords: Coronavirus disease 2019 (COVID-19); Fatty liver; Illness severity; Stay length.